Delivery Order SPE2DB22D2009-SPE2DB26FL5WL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,534.20 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This firm fixed price contract, awarded on August 15, 2025, represents a competitive award with no set-aside designation and will be completed by August 18, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,345.60 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count). This contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $17,816.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 10, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) valued at $19,488.02. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania headquarters. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,076.77 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 22, 2025. The award was made to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters location, which also serves as the place of performance for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,352.03 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This competitively awarded, firm fixed-price delivery order was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. The contract carries no set-aside designation, indicating that AmerisourceBergen competed openly against other qualified vendors. The pharmaceutical product will...
- The Defense Logistics Agency awarded a delivery order valued at $13,910.27 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) with a firm fixed price contract type. This award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $19,858.14 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply) under a firm fixed price contract. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $5,007.60 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used for chronic...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB26FL5WLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,176.22 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count). This firm fixed-price, non-set-aside delivery order was awarded on October 17, 2025, with an ultimate completion date of October 20, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems worldwide. TRELEGY ELLIPTA is a combination maintenance inhaler used for chronic obstructive pulmonary disease (COPD) treatment, reflecting the contractor's role in providing specialty respiratory medications to support Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 10/17/25 |